Total Payments
$105,681
2024 Payments
$23,998
Companies
44
Transactions
939
Medicare Patients
3,749
Medicare Billing
$1.3M
Payment Breakdown by Category
Research$53,423 (50.6%)
Other$26,000 (24.6%)
Food & Beverage$20,862 (19.7%)
Travel$4,992 (4.7%)
Education$403.94 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53,423 | 37 | 50.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,000 | 11 | 24.6% |
| Food and Beverage | $20,862 | 845 | 19.7% |
| Travel and Lodging | $4,992 | 25 | 4.7% |
| Education | $403.94 | 21 | 0.4% |
Payments by Type
Research
$53,423
37 transactions
General
$52,257
902 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lupin Inc. | $50,191 | 8 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $30,959 | 118 | $0 (2024) |
| GlaxoSmithKline, LLC. | $5,011 | 162 | $0 (2024) |
| AstraZeneca UK Limited | $2,013 | 9 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $1,829 | 19 | $0 (2021) |
| PFIZER INC. | $1,693 | 93 | $0 (2024) |
| GENZYME CORPORATION | $1,604 | 75 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,489 | 23 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $1,461 | 81 | $0 (2024) |
| CSL Behring | $1,180 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,998 | 150 | AstraZeneca Pharmaceuticals LP ($21,432) |
| 2023 | $10,409 | 153 | AstraZeneca Pharmaceuticals LP ($7,753) |
| 2022 | $3,211 | 147 | AstraZeneca Pharmaceuticals LP ($577.60) |
| 2021 | $2,490 | 134 | GlaxoSmithKline, LLC. ($374.16) |
| 2020 | $3,534 | 69 | GlaxoSmithKline, LLC. ($2,588) |
| 2019 | $2,571 | 82 | GlaxoSmithKline, LLC. ($535.77) |
| 2018 | $56,283 | 126 | Lupin Inc. ($50,191) |
| 2017 | $3,185 | 78 | Novartis Pharmaceuticals Corporation ($1,223) |
All Payment Transactions
939 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: Immunology and Neurology | ||||||
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $8.01 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/13/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $8.02 | General |
| Category: Inflammation & Immunology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: BIOLOGIC | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $33.92 | General |
| Category: RESPIRATORY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $10.54 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.09 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $8.53 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $38.65 | General |
| Category: Immunology | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $89.88 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/20/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: DERMATOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.32 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $8.85 | General |
| Category: Inflammation | ||||||
| 11/01/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $8.46 | General |
| Category: DERMATOLOGY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.60 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $46,691 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $3,500 | 1 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $2,415 | 17 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic O | SANOFI US SERVICES INC. | $667.57 | 11 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $150.49 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,052 | 18,046 | $622,461 | $320,857 |
| 2022 | 16 | 1,069 | 20,728 | $686,490 | $331,670 |
| 2021 | 12 | 881 | 20,526 | $927,282 | $318,573 |
| 2020 | 11 | 747 | 16,306 | $775,317 | $314,248 |
Total Patients
3,749
Total Services
75,606
Medicare Billing
$1.3M
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 13 | 6,225 | $342,375 | $187,929 | 54.9% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 114 | 3,227 | $64,540 | $39,038 | 60.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 271 | 424 | $57,240 | $27,645 | 48.3% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 67 | 5,177 | $41,416 | $16,880 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 165 | $25,575 | $15,413 | 60.3% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 110 | 1,172 | $29,300 | $10,210 | 34.8% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 84 | 717 | $14,340 | $5,158 | 36.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 63 | 63 | $9,765 | $5,147 | 52.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $8,740 | $4,522 | 51.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 357 | $16,065 | $3,814 | 23.7% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 65 | 402 | $4,020 | $2,742 | 68.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 74 | 79 | $9,085 | $2,359 | 26.0% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 18 | 8,725 | $405,693 | $192,858 | 47.5% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 102 | 3,030 | $60,600 | $39,179 | 64.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 228 | 342 | $41,710 | $22,369 | 53.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 140 | 192 | $28,815 | $18,608 | 64.6% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 70 | 5,398 | $43,184 | $18,070 | 41.8% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 100 | 1,218 | $30,450 | $10,266 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $13,510 | $7,779 | 57.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 45 | 505 | $23,463 | $5,772 | 24.6% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 72 | 637 | $12,740 | $4,219 | 33.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 54 | 54 | $7,860 | $4,047 | 51.5% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 63 | 379 | $3,790 | $2,787 | 73.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 15 | $3,150 | $2,260 | 71.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 61 | 67 | $7,705 | $2,220 | 28.8% |
About Dr. Amit Patel, MD
Dr. Amit Patel, MD is a Allergy & Immunology healthcare provider based in Upland, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396734547.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Patel, MD has received a total of $105,681 in payments from pharmaceutical and medical device companies, with $23,998 received in 2024. These payments were reported across 939 transactions from 44 companies. The most common payment nature is "" ($53,423).
As a Medicare-enrolled provider, Patel has provided services to 3,749 Medicare beneficiaries, totaling 75,606 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Allergy, Allergy & Immunology
- Location Upland, CA
- Active Since 10/20/2005
- Last Updated 08/05/2022
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1396734547
Products in Payments
- TIOTROPIUM (Drug) $46,691
- AIRSUPRA (Drug) $28,290
- NUCALA (Biological) $3,552
- ADVAIR (Drug) $3,500
- FASENRA (Drug) $2,271
- DUPIXENT (Biological) $2,081
- V160 (Biological) $1,751
- EUCRISA (Drug) $1,282
- TRELEGY ELLIPTA (Drug) $1,116
- RINVOQ (Biological) $901.71
- ADBRY (Biological) $817.81
- Haegarda (Biological) $805.86
- TEZSPIRE (Biological) $740.30
- SAR440340 (Drug) $667.57
- BREZTRI (Drug) $571.68
- CUVITRU (Biological) $557.97
- FASENRA (Biological) $544.14
- DUPIXENT DUPILUMAB INJECTION (Biological) $432.53
- RUCONEST (Biological) $416.79
- TAKHZYRO (Biological) $404.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.